CCA
SCPH

Catalyst Capital Advisors’s scPharmaceuticals SCPH Stock Holding History

Catalyst Capital Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-350
Closed -$4K – 558
2017
Q4 		$4K Buy
+350
New +$4.94K ﹤0.01% 405

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Catalyst Capital Advisors's SCPH Position: Q1 2018 in Review

Catalyst Capital Advisors sold out of scPharmaceuticals (SCPH) in Q1 2018, closing a stake of 350 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in SCPH in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 38 funds tracked by Wall St. Rank hold SCPH as of Q1 2018.

  • Catalyst Capital Advisors reported no remaining scPharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 350 scPharmaceuticals shares in Q1 2018, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in scPharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's scPharmaceuticals position peaked at $4K in Q4 2017.
  • 38 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2018.

Based on Catalyst Capital Advisors's 13F filing for Q1 2018, filed 18 May 2018.